Allergy Prior Auth: Biologics for Asthma and Allergies

The Biologic Revolution in Severe Asthma — and the Prior Auth Challenge

The introduction of targeted biologic therapies for severe asthma has transformed outcomes for patients who previously cycled through systemic corticosteroids, emergency department visits, and hospitalizations. Anti-IgE, anti-IL-5, anti-IL-4/13, and anti-TSLP biologics now offer individualized treatment based on a patient's specific inflammatory phenotype — but accessing these agents requires navigating complex prior authorization processes that vary significantly by payer and biologic class.

Severe asthma biologics cost $15,000–50,000 per patient per year, driving intensive payer scrutiny of authorization requests. The denial rate for initial biologic asthma authorization submissions averages 30–45% at major commercial payers — significantly higher than most other specialty biologic classes. This high denial rate reflects both the complexity of the eligibility criteria and widespread incomplete documentation at submission.

For allergy/immunology and pulmonology practices managing severe asthma patients, successful biologic authorization is the difference between transformative disease control and ongoing corticosteroid burden with its associated comorbidities. Prednisone-dependent severe asthmatics face cumulative toxicity from corticosteroids — osteoporosis, adrenal suppression, cataracts, hypertension, weight gain — that significantly worsens their overall health burden. Accurate documentation of corticosteroid burden (bursts per year, maintenance prednisone dose) is itself a compelling clinical argument for biologic access.

This guide covers the prior authorization pathways for the four major biologic classes in asthma — anti-IgE (omalizumab), anti-IL-5 (mepolizumab, benralizumab, reslizumab), anti-IL-4/IL-13 (dupilumab), and anti-TSLP (tezepelumab) — plus authorization considerations for subcutaneous and sublingual immunotherapy (SCIT/SLIT).

Anti-IgE: Omalizumab Authorization Criteria

Omalizumab (Xolair) was the first biologic approved for asthma (2003) and remains widely used for moderate-to-severe allergic asthma. Its payer authorization criteria are among the most well-defined in the asthma biologic space, making it paradoxically both easier and harder to authorize — easier because criteria are clear, harder because patients who don't meet them precisely are denied.

FDA approval and payer coverage criteria for omalizumab in asthma: 1. Age: ≥6 years old 2. Diagnosis: Moderate-to-severe persistent asthma (GINA Step 3–5 treatment) 3. Allergic sensitization: Positive skin test OR specific IgE to a perennial aeroallergen (house dust mite, cat, dog, cockroach, alternaria, aspergillus, or other year-round allergen). Point-of-care specific IgE testing or formal allergy skin test documentation must be included in the auth submission. 4. Baseline serum total IgE: 30–1,500 IU/mL — omalizumab is not indicated below 30 or above 1,500 because the dosing nomogram is calibrated to this range. The IgE level (within 12 months) must be included in the authorization. 5. Inadequate control on inhaled corticosteroids: Documented persistent symptoms (≥2 days/week symptoms, nighttime awakenings, SABA rescue use) despite medium-to-high dose ICS ± LABA.

Dosing calculation: Omalizumab dose (75–375 mg SC every 2 or 4 weeks) is determined by baseline IgE level and body weight using the FDA-approved dosing table. The authorization should specify the exact dose and frequency per the nomogram — payers may question dosing that deviates from the published table.

Additional omalizumab indications requiring separate authorization: chronic idiopathic urticaria (CIU/CSU — ≥12 years, IgE range not required for this indication, 150 or 300 mg every 4 weeks), nasal polyps (≥18 years, 2024 FDA approval). Each indication may have different payer coverage criteria — verify indication-specific criteria before submitting.

Anti-IL-5 Agents: Mepolizumab and Benralizumab — Eosinophil Thresholds

Anti-IL-5 biologics target the eosinophilic inflammation pathway and are indicated for severe eosinophilic asthma — a phenotype characterized by elevated blood and/or tissue eosinophils. Three anti-IL-5 or anti-IL-5Rα agents are FDA-approved: mepolizumab (Nucala), benralizumab (Fasenra), and reslizumab (Cinqair). The eosinophil count threshold in prior authorization is the defining eligibility criterion.

Mepolizumab (Nucala) — anti-IL-5 antibody: - Indication: Severe eosinophilic asthma, ≥6 years - Blood eosinophil threshold: Most payers require ≥150–300 cells/μL within the past 12 months. Some payers require ≥300 as the primary threshold, accepting ≥150 with 2+ exacerbations in the prior year. The authorization submission must include the actual eosinophil count (not just a statement of elevated eosinophils) with the date of the CBC differential. - Dose: 100 mg SC every 4 weeks - Additional approved indications: eosinophilic granulomatosis with polyangiitis (EGPA), hypereosinophilic syndrome (HES), CRS with nasal polyps — each with separate authorization criteria

Benralizumab (Fasenra) — anti-IL-5Rα antibody: - Indication: Severe eosinophilic asthma, ≥12 years - Blood eosinophil threshold: ≥300 cells/μL within the past 12 months is the most common payer requirement. Some payers accept ≥150 with documented exacerbation history. The mechanism difference (anti-receptor vs. anti-cytokine) translates to more complete eosinophil depletion — relevant to patients with incomplete mepolizumab response. - Dosing schedule: 30 mg SC every 4 weeks × 3 doses (loading), then every 8 weeks maintenance — the Q8W maintenance is a practical adherence advantage. Authorization should specify both phases.

Reslizumab (Cinqair) — anti-IL-5 antibody (IV formulation): - Indication: Severe eosinophilic asthma, ≥18 years - Eosinophil threshold: ≥400 cells/μL - IV formulation: 3 mg/kg every 4 weeks administered in a clinical setting — office infusion capability required. Less commonly used than the SC agents due to IV administration burden.

Eosinophil count documentation tips: Include the complete CBC with differential from the lab report (not just the eosinophil number extracted into the auth form). If the patient is already on systemic corticosteroids, note that steroids suppress eosinophil counts — a count of 150 on steroids may reflect a higher pre-treatment baseline. Include pre-steroid eosinophil counts if available.

Anti-IL-4/IL-13: Dupilumab for Asthma and Atopic Dermatitis

Dupilumab (Dupixent) is the broadest-indication biologic in the allergy space, with FDA approvals covering moderate-to-severe atopic dermatitis (≥6 months), moderate-to-severe asthma (≥6 years), CRS with nasal polyps (≥18 years), eosinophilic esophagitis (≥12 years), and prurigo nodularis (≥18 years). This multi-indication profile makes dupilumab authorization complex — criteria differ substantially by indication.

Dupilumab for moderate-to-severe asthma: - Step therapy requirement: Inadequate control on medium-to-high dose ICS + additional controller medication (LABA or leukotriene modifier) - Eosinophil or FeNO threshold: Many payers require blood eosinophils ≥150 cells/μL OR FeNO ≥25 ppb as a biomarker of type 2 inflammation (dupilumab is most effective in type 2-high asthma). Include the laboratory eosinophil count OR FeNO measurement (exhaled nitric oxide testing, CPT 95012) in the submission. - Exacerbation history: ≥2 exacerbations requiring OCS in the prior 12 months OR maintenance OCS use - Dose: 200 or 400 mg SC every 2 weeks (dose by severity)

Dupilumab for atopic dermatitis (AD): - Severity threshold: IGA ≥3 (moderate) on a 0–4 scale, or EASI ≥16 (moderate-to-severe) - Step therapy: Inadequate response to topical corticosteroids and/or topical calcineurin inhibitors; some payers require failure of systemic agents (cyclosporine, MTX, dupilumab's competitor agents) - For AD, eosinophil counts are NOT required for authorization — this is a common documentation confusion that practices fall into when repurposing asthma auth templates for AD

Dupilumab for nasal polyps: - Endoscopic confirmation of bilateral polyps is required for most payers - Prior treatment: Intranasal corticosteroid spray and saline rinse, systemic corticosteroid trial - Prior sinus surgery is often required or preferred by payers

Multi-indication dupilumab patients — e.g., a patient with both AD and asthma — require authorization for each indication separately, though the drug is the same. Some payers allow a single auth covering all approved indications simultaneously; others require separate submissions per indication. Verify payer-specific policy.

Anti-TSLP: Tezepelumab for Severe Uncontrolled Asthma

Tezepelumab (Tezspire) is the newest asthma biologic (FDA approved December 2021) and represents a significant advance in that it is the first biologic effective across all severe asthma phenotypes — eosinophilic and non-eosinophilic — because it targets TSLP (thymic stromal lymphopoietin), an upstream epithelial cytokine that drives both type 2 and non-type 2 inflammation.

This broad mechanism means that tezepelumab is the appropriate biologic for severe uncontrolled asthma patients who do not have elevated eosinophils or IgE — patients who are ineligible for other biologics due to failing to meet biomarker thresholds. However, payer coverage criteria have not uniformly embraced this broad indication — many payers still require eosinophil counts or other biomarkers despite the FDA label having no eosinophil or IgE threshold requirement.

Standard payer criteria for tezepelumab (vary by plan): - Moderate-to-severe persistent asthma on GINA Step 4–5 therapy (high-dose ICS + LABA ± additional controller) - ≥2 exacerbations requiring systemic corticosteroids in the prior 12 months - Some payers: No eosinophil threshold (aligning with FDA label); others: eosinophils <150 (positioning tezepelumab as the biologic for non-eosinophilic asthma after failure of anti-IL-5 agents) - Most payers: Step therapy through at least one other asthma biologic

Authorization strategy for non-eosinophilic asthma patients: For patients who fail to meet the eosinophil threshold for anti-IL-5 biologics and the IgE threshold for omalizumab, tezepelumab is the correct clinical choice. The authorization letter should explicitly state: patient's eosinophil count (below threshold for anti-IL-5 biologics), patient's IgE level (below threshold or no allergic sensitization for omalizumab), and why tezepelumab's mechanism is appropriate. This clear phenotype-to-drug matching improves approval rates.

Dose: 210 mg SC every 4 weeks, fixed dose regardless of eosinophil count or body weight — simplifying dosing compared to omalizumab.

Exacerbation Documentation: The Core of Severe Asthma Authorization

Regardless of the specific biologic being requested, exacerbation history documentation is the most critical element of severe asthma prior authorization. Payers require exacerbation data to establish that the asthma is truly severe and uncontrolled — not just inadequately treated or suboptimally adherent. Without robust exacerbation documentation, no asthma biologic will be approved.

What counts as a qualifying exacerbation: Asthma exacerbation for prior auth purposes typically requires one or more of: systemic corticosteroid course (OCS ≥3 days, or IM depot steroid injection), ED visit for acute asthma, hospitalization for acute asthma. Most payers require ≥2 qualifying exacerbations in the prior 12 months. Some allow 1 severe exacerbation (hospitalization) as sufficient.

Documentation sources for exacerbation history: Practice EHR records showing OCS prescriptions (date, dose, duration), ED or hospital discharge summaries, pharmacy dispensing records for prednisolone/prednisone (obtainable from PBM). For exacerbations that occurred outside your practice, obtain records from the ED or hospital — even a brief note showing asthma-related discharge is sufficient.

Organizing exacerbation data for authorization: Create a 12-month exacerbation summary table: date, type (OCS burst, ED, hospital), treatment, and resolution. This table, attached to the PA submission, presents the exacerbation history in a format that reviewers can quickly evaluate. Practices that narrate exacerbation history in paragraph form have lower first-pass approval rates than those presenting tabulated data.

Asthma control questionnaires — ACT (Asthma Control Test) and ACQ (Asthma Control Questionnaire) — should be administered at each clinic visit for all moderate-to-severe asthma patients. ACT score ≤19 indicates uncontrolled asthma; ACQ score ≥1.5 indicates inadequate control. Include the most recent questionnaire score in the authorization. These standardized scores provide objective evidence of inadequate control even between exacerbation events.

SCIT vs. SLIT Authorization: Subcutaneous vs. Sublingual Immunotherapy

Immunotherapy authorization — for both subcutaneous (SCIT, allergy shots) and sublingual (SLIT, sublingual drops or tablets) — has its own payer-specific requirements that differ from biologic medication authorization.

SCIT authorization: Most commercial payers and Medicare cover subcutaneous allergy immunotherapy for allergic rhinitis, allergic asthma, venom hypersensitivity, and some atopic dermatitis with positive allergen skin testing or specific IgE confirming sensitization. Authorization is generally straightforward — submit: allergist letter of medical necessity, skin test or RAST results showing relevant sensitization, and the prescribed extract formulation. Some plans require a prior trial of pharmacotherapy (antihistamines, intranasal corticosteroids) before authorizing immunotherapy.

SLIT tablet authorization: FDA-approved SLIT tablets — Grastek (timothy grass), Ragwitek (ragweed), Odactra (house dust mite), Palforzia (peanut — food allergy protocol) — require prior authorization from most commercial payers. Coverage criteria: confirmed sensitization to the specific allergen (skin test or specific IgE), diagnosis of allergic rhinitis or asthma with the specific allergen trigger, and in some plans, a trial of SCIT or documentation of why SCIT is inappropriate. SLIT tablets are self-administered at home after the first dose (administered in the office with 30-minute observation for all SLIT tablets — this is an in-office visit that should be scheduled and billed as a procedure visit).

SLIT drops authorization: Non-FDA-approved SLIT drops (off-label in the US) are typically not covered by insurance and are a cash-pay service. Practices offering SLIT drops should communicate this clearly to patients at enrollment.

Venom immunotherapy: Hymenoptera venom allergy (bee, yellow jacket, wasp, hornet — Melittin, Vespula, Polistes species) immunotherapy is strongly evidence-supported for anaphylaxis prevention. Authorization requires: documented anaphylactic reaction to specific venom, confirmed sensitization (skin test with venom extracts or specific IgE). Venom immunotherapy is covered by most major payers with appropriate documentation — the key submission element is a clear narrative of the anaphylactic episode, including epinephrine use.

Denial Management and Appeals for Asthma Biologics

Given the 30–45% initial denial rate for asthma biologics at major commercial payers, having a structured appeal process is essential for allergy/immunology practices. Appeals for asthma biologics are successful at higher rates than many other specialty drugs — peer-to-peer reviews reverse 55–70% of initial denials — making investment in the appeal process highly worthwhile.

Common denial reasons and appeal responses:

*"Insufficient step therapy"*: The payer requires a trial of a less expensive biologic before the requested agent. Appeal response: document why the initially requested agent is the most appropriate clinical choice for this patient's phenotype (e.g., non-eosinophilic asthma phenotype makes anti-IL-5 agents inappropriate; document the eosinophil count). If step therapy is genuinely required, explore whether a step therapy exception applies (patient's clinician determines the step agent is contraindicated or clinically inappropriate — enforceable under state step therapy laws in 22+ states).

*"Eosinophil count below threshold"*: For anti-IL-5 agents, if the eosinophil count is borderline (e.g., 180 cells/μL against a 300 threshold), appeal with: historical counts showing the patient's eosinophils have previously exceeded threshold, note that systemic corticosteroid use at time of measurement suppresses counts, and include FeNO measurement as a corroborating type 2 biomarker.

*"IgE outside dosing range"* (for omalizumab): If IgE is above 1,500 IU/mL, omalizumab is not FDA-approved. Consider switching to dupilumab or tezepelumab — both effective regardless of IgE level.

*"Asthma not adequately severe"*: Supplement with: all available exacerbation records, emergency visit records, current ACT/ACQ scores, and a peer-reviewed clinical reference establishing that the patient's presentation meets published severe asthma criteria (e.g., ERS/ATS Severe Asthma Guidelines 2014, updated 2022).

Renewal authorization for asthma biologics should include: most recent exacerbation rate (improved on biologic — typically 40–50% reduction), current ACT score, current OCS dose (reduction from baseline demonstrates treatment efficacy), and spirometry results if available. Demonstrating clinical response is the foundation of renewal success.